‘Excellent’ Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received, a Dutch registry study showed. After a median follow-up of 6 years, regional recurrence rates ranged from 3.0-4.1% whether they had conservative axillary surgery […]
What Is Luminal B Breast Cancer? Olivia Munn’s Diagnosis Explained.
Phillip Faraone/VF24 via Getty Images Luminal B breast cancer tends to be more aggressive and often presents at later stages. Actress Olivia Munn announced on Instagram that she was diagnosed with breast cancer in 2023. Specifically, Munn was diagnosed with luminal B breast cancer, which is one of the molecular subtypes of breast cancer, according […]
In TNBC, Pathologic Complete Response May Vary by Race/Ethnicity
Among patients with triple-negative breast cancer (TNBC) who received neoadjuvant chemotherapy, the odds of achieving pathologic complete response (pCR) and improved overall survival (OS) may vary by race/ethnicity, according to results from a retrospective cohort study. Compared with white women, Black women with TNBC were less likely to achieve pCR (OR 0.89, 95% CI 0.83-0.95, […]
Financial Toxicity Among Single Mothers With Metastatic Breast Cancer
A study presented at the San Antonio Breast Cancer Symposium highlighted financial toxicity in underserved/underrepresented single mothers living with metastatic breast cancer, and how the situation can affect their physical, mental, and emotional health. In this exclusive MedPage Today video, Maryam Lustberg, MD, director of the Center for Breast Cancer at the Yale School of […]
Clinical Challenges: Test Your Knowledge of Breast Cancer
A MedPage Today Clinical Challenges series on breast cancer reviewed locoregional therapy for older patients, the management of invasive lobular cancer (ILC), and the treatment of advanced hormone receptor (HR)-positive disease post-CDK4/6 inhibition. The following is a three-question quiz to test your knowledge on each aspect of the series. Correct answers and explanations appear after […]
Manipulation of gut microbiota with flaxseed could reduce breast cancer risk
A new study demonstrates that the human gut microbiome may be a factor in breast health. Lifestyle and diet have long been known to affect human health. In the study, flaxseed components called lignans were shown to influence the relationship between gut microorganisms and the expression of mammary gland microRNAs (miRNAs). A subset of these […]
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer
SAN ANTONIO — Bilateral mastectomy as initial treatment for women with breast cancer and a pathogenic BRCA1 variant was not linked to better survival, according to an international analysis. Compared with breast-conserving treatment (BCT), bilateral mastectomy was not significantly associated with a reduction in mortality in this population of patients (HR 0.83, P=0.52), reported Kelly […]
Clinical Challenges: Test Your Knowledge on New Breast Cancer Treatments
The number of available treatment options for patients newly diagnosed with breast cancer continues to grow. The following three-question quiz will test one aspect from each article in our “Clinical Challenges” series on advanced breast cancer, which covered managing adverse effects of novel therapies and sequencing of treatments in metastatic HER2-positive breast cancer and metastatic […]
Clinical Challenges: Sequencing in Metastatic TNBC
As new treatment options continue to emerge for triple-negative breast cancer (TNBC), sequencing of therapy promises to get ever more complicated. TNBC had been estimated to account for about 15% of all breast cancer diagnoses, but that proportion shrank with the new HER2-low designation, which accounts for approximately one-third of patients diagnosed with TNBC. An […]
Clinical Challenges: Sequencing in Metastatic, HER2-Positive Breast Cancer
In the last few years there has been tremendous progress in the treatment of metastatic HER2-positive breast cancer. “We are getting a lot of therapeutic options coming into this space,” said Shridar Ganesan, MD, PhD, a physician-scientist at the Rutgers Cancer Institute of New Jersey. “Trastuzumab [Herceptin] was the first, but we now have a […]